Use of the activating gene mutation of the tyrosine kinase (VAL617Phe) JAK2 as a minimal residual disease marker in patients with myelofibrosis and myeloid metaplasia after allogeneic stem cell transplantation (Q80470329)
Jump to navigation
Jump to search
scientific article published on 01 June 2007
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Use of the activating gene mutation of the tyrosine kinase (VAL617Phe) JAK2 as a minimal residual disease marker in patients with myelofibrosis and myeloid metaplasia after allogeneic stem cell transplantation |
scientific article published on 01 June 2007 |
Statements
Use of the activating gene mutation of the tyrosine kinase (VAL617Phe) JAK2 as a minimal residual disease marker in patients with myelofibrosis and myeloid metaplasia after allogeneic stem cell transplantation (English)
Nina K Steckel
Michael Koldehoff
Markus Ditschkowski
Dietrich W Beelen
Ahmet H Elmaagacli